Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Mar 31, 2017

Filed with the SEC on May 5, 2017 and accepted by EDGAR at May 5, 2017, 16:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2017-01-01 to 2017-03-31$184.5kus-gaap:SalesRevenueNet
Research and development3 months2017-01-01 to 2017-03-31$1.8mus-gaap:ResearchAndDevelopmentExpense
Interest expense3 months2017-01-01 to 2017-03-31$303us-gaap:InterestExpense
Diluted EPS3 months2017-01-01 to 2017-03-31−$0.28us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2017-03-31$5.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-03-31$6.4mus-gaap:AssetsCurrent
Total assetsAt period end2017-03-31$12.0mus-gaap:Assets
Current liabilitiesAt period end2017-03-31$10.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-03-31$13.1mus-gaap:Liabilities
Shareholders' equityAt period end2017-03-31−$1.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-024841. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.